Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

Yang Yang Ding; Jessica Panzer; John M. Maris; Alicia Castañeda; Marta Gomez-Chiari; Jaume Mora

doi:10.1002/pbc.26732

Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

Yang Yang Ding, Jessica Panzer, John M. Maris, Alicia Castañeda, Marta Gomez-Chiari, Jaume Mora

Research output: Contribution to journal › Article › peer-review

Abstract

Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery.

Original language	English (US)
Article number	e26732
Journal	Pediatric Blood and Cancer
Volume	65
Issue number	1
DOIs	https://doi.org/10.1002/pbc.26732
State	Published - Jan 2018
Externally published	Yes

Keywords

anti-GD2 monoclonal antibody
dinutuximab
neuroblastoma
transverse myelitis
Unituxin

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.26732

Cite this

@article{fe12b4ea70004ba28b082e4216bd6f75,

title = "Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series",

abstract = "Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery.",

keywords = "anti-GD2 monoclonal antibody, dinutuximab, neuroblastoma, transverse myelitis, Unituxin",

author = "Ding, {Yang Yang} and Jessica Panzer and Maris, {John M.} and Alicia Casta{\~n}eda and Marta Gomez-Chiari and Jaume Mora",

note = "Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",

year = "2018",

month = jan,

doi = "10.1002/pbc.26732",

language = "English (US)",

volume = "65",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma

T2 - A case series

AU - Ding, Yang Yang

AU - Panzer, Jessica

AU - Maris, John M.

AU - Castañeda, Alicia

AU - Gomez-Chiari, Marta

AU - Mora, Jaume

PY - 2018/1

Y1 - 2018/1

N2 - Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery.

AB - Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has not been reported in clinical trials or in the published literature. We describe three patients with clinical symptoms of transverse myelitis, confirmed via magnetic resonance imaging, shortly following initiation of dinutuximab. All patients were discontinued from dinutuximab treatment and received urgent treatment, with rapid improvement in symptoms and resultant functional recovery.

KW - anti-GD2 monoclonal antibody

KW - dinutuximab

KW - neuroblastoma

KW - transverse myelitis

KW - Unituxin

UR - http://www.scopus.com/inward/record.url?scp=85026420198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026420198&partnerID=8YFLogxK

U2 - 10.1002/pbc.26732

DO - 10.1002/pbc.26732

M3 - Article

C2 - 28748630

AN - SCOPUS:85026420198

SN - 1545-5009

VL - 65

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

M1 - e26732

ER -

Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this